Taiba Middle East
Plot 564, Rusayl Industrial Area, Muscat, Muscat Governorate, 111, Oman
Overview
taiba plays a pioneering role in the management of orphan drugs and treatments for rare diseases. As a leader in providing services and treatment of such diseases, they have played a vital role in improving people's health and quality of life. Their mission is and will always be to improve lives, by providing quality products and services to health care organizations through their global network of partners.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Pharmaceutical
Investment portfolio
- Immuneel Therapeutics
Led · Series A · Jul 2024
Immuneel Therapeutics develops CAR-T cell therapies, including Qartemi, aimed at treating blood cancers. The company describes CAR-T as a process that extracts a patient’s immune cells, modifies them to target cancer cells, and reinfuses them. Immuneel was founded in Bengaluru in 2019 and is led by Kiran Mazumdar-Shaw. Financially, the company recently raised Rs 100 crore ($10.5 million) in a Series B and previously secured $15 million in a 2022 Series A. Immuneel plans to use the new capital to ramp up production capacity for Qartemi and to expand its commercial or clinical efforts into Southeast Asia and the Middle East.
Team
No current team members are available.